A recent report in Nature (Dec. 15, 2016) has identified 17 unique gene expression signatures for AML in leukemic stem cells, which could be useful in predicting “targeted therapies” and has the potential to become valuable prognostics indicators? How we use this info for extrapolating these (and other) differentially expressed genomic profiles for solid tissue cancers? Do we expect to see altogether different gene expression signatures in solid cancer's stem cells? How these differentially expressed individual genes (and their corresponding proteins) could help us find better biomarkers for early diagnosis and reliable prognosis prediction of individual patient's response to therapy. In the immediate near future, scientists and clinicians might be able to “design personalized medicine” strategies against key “driver genes” with the ultimate hope of making cancer “a manageable disease”. Furthermore, how we may use this info for futuristic and personalized new drug discovery research tool is certainly optimistic, and will lead to designing "magic bullets" against various cancers, which we have been hoping for a while now........
Dear Kulvinder,
The whole genome sequencing data and analysis from the cancer patients will bring us much closer to the development of personalized successful therapies than targeted therapies of one gene or one signaling pathway. Personalized therapy is advancing and there are very many conferences to attend to find this information and collaborations.
Best wishes and kind regards,
- Badges
- Science topic
- Similar topics
- Medicine
- Oncology
- Cancer Research
- Cancer Biology
- Cancer Cells
- Cancer Stem Cells